CO5170529A1 - Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida - Google Patents

Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida

Info

Publication number
CO5170529A1
CO5170529A1 CO00039601A CO00039601A CO5170529A1 CO 5170529 A1 CO5170529 A1 CO 5170529A1 CO 00039601 A CO00039601 A CO 00039601A CO 00039601 A CO00039601 A CO 00039601A CO 5170529 A1 CO5170529 A1 CO 5170529A1
Authority
CO
Colombia
Prior art keywords
alkyl
metil
hydrogen
alkoxy
halogen
Prior art date
Application number
CO00039601A
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5170529A1 publication Critical patent/CO5170529A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de fórmula general:<EMI FILE="00039601_1" ID="1" IMF=JPEG >en dondeR1 es hidrógeno o halógeno;R2 es hidrógeno, halógeno, alquilo C1-C7 o alcoxilo C1-C7;R3 es halógeno, trifluorometilo, alcoxilo C1-C7 o alquilo C1-C7 ;R4/R4´ son independientemente entre sí, hidrógeno o alquilo C1-C7;R5 es alquilo C1-C7, alcoxilo C1-C7, amino, hidroxilo, hidroxialquilo C1-C7, -(CH2)n-piperazinilo, -(CH2)n-morfolinilo opcionalmente substituido con alquilo C1-C7, -(CH2)n+1-imidazolilo, -O-(CH2)n+1-morfolinilo, -O-(CH2)n+1-piperidinilo, alquilo C1-C7-sulfanilo, alquilo C1-C7-sulfonilo, bencilamino, -NH-(CH2)n+1 N(R4")2, -(CH2)n-NH-(CH2)n+1N(R4")2, -(CH2)n+1N(R4")2, ó -O-(CH2)n+1N(R4")2 en donde R4" es hidrógeno o alquilo C1-C7;R6 es hidrógeno;R2 y R6 ó R1 y R6 pueden ser juntamente con los dos átomos de carbono del anillo, -CH=CH-CH=CH-, con la condición de que n para R1 sea 1;n es independientemente 0 - 2; yX es -C(O)N(R4" )- ó N(R4" )C(O)-;o las sales de adición ácida farmacéuticamente aceptables de los mismos.
CO00039601A 1999-05-31 2000-05-29 Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida CO5170529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31

Publications (1)

Publication Number Publication Date
CO5170529A1 true CO5170529A1 (es) 2002-06-27

Family

ID=8238270

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00039601A CO5170529A1 (es) 1999-05-31 2000-05-29 Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida

Country Status (36)

Country Link
US (1) US6756380B1 (es)
EP (1) EP1187814B1 (es)
JP (1) JP3590591B2 (es)
KR (1) KR100478369B1 (es)
CN (1) CN1187338C (es)
AR (1) AR024145A1 (es)
AT (1) ATE273962T1 (es)
AU (1) AU769265B2 (es)
BR (1) BR0011097A (es)
CA (1) CA2375670C (es)
CO (1) CO5170529A1 (es)
CZ (1) CZ20014273A3 (es)
DE (1) DE60013127T2 (es)
DK (1) DK1187814T3 (es)
ES (1) ES2225144T3 (es)
GC (1) GC0000338A (es)
HK (1) HK1046411B (es)
HR (1) HRP20010867A2 (es)
HU (1) HU225016B1 (es)
IL (2) IL146519A0 (es)
JO (1) JO2308B1 (es)
MA (1) MA26794A1 (es)
MX (1) MXPA01011704A (es)
MY (1) MY136258A (es)
NO (1) NO321334B1 (es)
NZ (1) NZ515408A (es)
PE (1) PE20010203A1 (es)
PL (1) PL353492A1 (es)
PT (1) PT1187814E (es)
RU (1) RU2244710C2 (es)
SI (1) SI1187814T1 (es)
TR (1) TR200103460T2 (es)
TW (1) TWI263638B (es)
WO (1) WO2000073278A2 (es)
YU (1) YU85001A (es)
ZA (1) ZA200109496B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
DE60113104D1 (de) * 2000-06-13 2005-10-06 Basf Ag 5 phenyl substituierte 2-(cyanoamino)-pyrimidine als fungizide
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
BR0312358A (pt) 2002-07-02 2005-04-05 Hoffmann La Roche Derivados de pirimidina 2,5-substituìda como antagonistas ix de receptor de ccr-3
EP1689403A4 (en) * 2003-11-10 2007-09-05 Synta Pharmaceuticals Corp HETEROARYL-hydrazone compounds
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
US7696202B2 (en) * 2004-11-10 2010-04-13 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA2906931C (en) 2013-03-15 2023-03-14 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
KR20170107536A (ko) 2015-01-30 2017-09-25 바스프 에스이 제초 페닐피리미딘
WO2018015180A1 (en) 2016-07-20 2018-01-25 Basf Se Herbicidal compositions comprising phenylpyrimidines
BR112018076642A2 (pt) 2016-07-25 2019-03-26 Basf Se compostos de pirimidina, compostos de pirimidina de fórmula e seu uso, composições herbicidas, método de controle de vegetação indesejada e uso das composições
CA3030082A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
CN109476647A (zh) 2016-07-26 2019-03-15 巴斯夫欧洲公司 除草的嘧啶化合物
EP3490381A1 (en) 2016-07-27 2019-06-05 Basf Se Herbicidal pyrimidine compounds
WO2018019574A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyrimidine compounds
EP3638033A1 (en) 2017-06-14 2020-04-22 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
ES2959616T3 (es) 2018-09-19 2024-02-27 Bayer Ag Hidrazidas de fenilpirimidina sustituidas con efecto herbicida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
SG52217A1 (en) 1993-12-29 1998-09-28 Merck Sharp & Dohme Substituted morpholine derivatives and their use as therapeutic agents
AU726522B2 (en) 1995-09-01 2000-11-09 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions

Also Published As

Publication number Publication date
JP2003500477A (ja) 2003-01-07
NO20015701D0 (no) 2001-11-22
ES2225144T3 (es) 2005-03-16
HRP20010867A2 (en) 2003-04-30
WO2000073278A2 (en) 2000-12-07
MXPA01011704A (es) 2002-05-14
NZ515408A (en) 2004-02-27
EP1187814A2 (en) 2002-03-20
PE20010203A1 (es) 2001-02-15
CZ20014273A3 (cs) 2002-05-15
AU5070800A (en) 2000-12-18
NO321334B1 (no) 2006-04-24
PL353492A1 (en) 2003-11-17
MA26794A1 (fr) 2004-12-20
JO2308B1 (en) 2005-09-12
BR0011097A (pt) 2002-03-19
CN1353696A (zh) 2002-06-12
WO2000073278A3 (en) 2001-07-05
AU769265B2 (en) 2004-01-22
EP1187814B1 (en) 2004-08-18
HUP0201527A3 (en) 2005-01-28
IL146519A (en) 2006-12-10
YU85001A (sh) 2004-09-03
HK1046411B (zh) 2005-05-27
KR20020003399A (ko) 2002-01-12
HU225016B1 (en) 2006-05-29
HK1046411A1 (en) 2003-01-10
HUP0201527A2 (en) 2002-08-28
MY136258A (en) 2008-09-30
TWI263638B (en) 2006-10-11
CA2375670C (en) 2009-09-29
ZA200109496B (en) 2003-02-17
DE60013127D1 (de) 2004-09-23
SI1187814T1 (en) 2004-12-31
DK1187814T3 (da) 2004-12-20
US6756380B1 (en) 2004-06-29
RU2244710C2 (ru) 2005-01-20
DE60013127T2 (de) 2005-09-08
ATE273962T1 (de) 2004-09-15
JP3590591B2 (ja) 2004-11-17
TR200103460T2 (tr) 2002-05-21
IL146519A0 (en) 2002-07-25
AR024145A1 (es) 2002-09-04
NO20015701L (no) 2001-11-22
CA2375670A1 (en) 2000-12-07
GC0000338A (en) 2007-03-31
PT1187814E (pt) 2004-10-29
CN1187338C (zh) 2005-02-02
KR100478369B1 (ko) 2005-03-24

Similar Documents

Publication Publication Date Title
CO5170529A1 (es) Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
CO5251467A1 (es) Derivados de piperazina
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
CY1105688T1 (el) Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης
ATE220677T1 (de) Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung
HUP0004439A2 (hu) 1-Helyettesített-1-amino-metil-cikloalkán-származékok (gabapentin analógok), a vegyületek előállítása és neurológiai rendellenességek kezelésében való alkalmazása
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
HUP0301236A2 (hu) Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
ES8200011A1 (es) Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa.
EE04308B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
GB9300194D0 (en) Piperazine derivatives
CO5170520A1 (es) Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida
SE7501365L (es)
PE42898A1 (es) Nuevos derivados de 2-(3h)-oxazolona
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
ES8401012A1 (es) Un procedimiento para la preparacion de nuevos derivados de propanolamina.
ES2060079T3 (es) Procedimiento para la preparacion de un carboxialquil-eter de la 2-amino-7-hidroxitetralina.
HUP9903526A2 (hu) Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
HUP0004317A2 (hu) 5-HT1F agonisták
ES8600230A1 (es) Procedimiento para preparar nuevos bis-(piperazinil- u homopiperazinil)-alcanos
ES520314A0 (es) Procedimiento para la preparacion de nuevas 4-fenil-4,5,6,7-tetrahidro-tieno (2,3-c)piridinas sustituidas con radicales basicos.
MXPA04002838A (es) Derivados de alquilaminopiridazinona sustituidos, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FD Application lapsed